Menu
Oslo, Norway, 13 March 2026 – Reference is made to the stock exchange announcement made by Thor Medical ASA on 27 February 2026 regarding issuance of new shares in connection with exercise of share options under the Company's incentive program.
The share capital increase has now been registered in the Norwegian Register of Business Enterprises and the Company's new share capital is NOK 71,956,459.80 divided by 359,782,299 shares, each with a nominal value of NOK 0.20. Each share represents one vote in the Company's general meeting.
For further information please contact:
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
Tel: +47 988 05 724
mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Securities Trading Act.
